Dietary Advanced Glycation End-products and Insulin Resistance in Overweight and Obese Humans
We hypothesize that reduction in dietary advance glycation endproducts (AGE) intake will increase insulin sensitivity and normalise insulin secretion in overweight and obese individuals through reduction of chronic low grade inflammation.
We propose to test this hypothesis by performing euglycemic hypeinsulinemic glucose clamp and intravenous glucose tolerance test before and after low AGE diet and normal Australian diet in a cross-over design. This study will provide information relevant to the development and prevention of type 2 diabetes.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Prevention
|Official Title:||Will Reduction in Dietary Advanced Glycation End- Products Reduce Chronic Low Grade Inflammation and Improve Insulin Sensitivity in Overweight and Obese Humans|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00422253
|Baker Heart Research Insitute|
|Melbourne, Victoria, Australia, 3186|
|Principal Investigator:||Barbora de Courten, MD PhD||Baker Heart Research Institute|